
Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery
pharmafile | January 10, 2020 | News story | Medical Communications | Bayer, Exscientia, oncology
Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development, said: “The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures.”
Exscientia, a leading AI drug discovery company, will apply its Centaur Chemist AI drug discovery platform to discover and optimise drug candidates. Exscientia will initially work on three projects, with the targets agreed between them and Bayer.
Exescientia may be eligible to receive €240 million. This could include research payments and sales royalties.
Professor Andrew Hopkins, Chief Executive Officer of Exscientia, said: “We’re delighted to collaborate with Bayer, a globally recognised pharmaceutical company. Since our pioneering Nature papers demonstrating the automated design of small molecules, we have enhanced our platform and exemplified it commercially, by accelerating the discovery of future drug molecules with partners.”
Conor Kavanagh
Related Content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …




